Ấn Độ không quan ngại về tác dụng phụ của vaccine AstraZeneca

Ngày 17/3, quan chức y tế Ấn Độ Vinod Kumar Paul khẳng định rằng nước này không lo ngại về tác dụng phụ tiềm ẩn của vaccine AstraZeneca đang được sử dụng trong chương trình tiêm chủng quốc gia.

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

Bình luận

Xin vui lòng gõ tiếng Việt có dấu

Tin cùng chuyên mục

Chi phí chiến sự Iran của Mỹ vượt 47 tỷ USD

Chi phí chiến sự Iran của Mỹ vượt 47 tỷ USD

Thế giới
(Baothanhhoa.vn) - Dữ liệu mới nhất từ Lầu Năm Góc tính đến ngày 16/10 cho thấy chi phí quân sự của Mỹ trong cuộc chiến với Iran đã vượt mốc 47 tỷ USD, trong đó phần lớn ngân sách được dùng vào việc thay thế các loại đạn dược và khí tài đã tiêu hao.
Chứng nhận tín nhiệm mạng
Việt Long Phần mềm tòa soạn
hội tụ thông minh